NMN is not established as a treatment for menopause symptoms. A trial in postmenopausal women measured muscle insulin sensitivity; that is not the same question as hot flashes or night sweats. A newer symptom study tested a different combination—NR plus pterostilbene—and its preliminary design cannot establish benefits for NMN products. NMN trial; NR combination pilot.
If you are considering NMN during midlife, start with the outcome you want evidence for. “Studied in women,” “supports NAD+” and “helps menopause symptoms” are different claims. A useful purchase decision keeps those claims separate.
What did the NMN trial in women actually test?
The finding was about muscle response to insulin in a specific metabolic-risk group. The 2021 randomized, double-blind, placebo-controlled study included 25 postmenopausal women with prediabetes and overweight or obesity. After ten weeks, NMN improved muscle insulin sensitivity and related signaling measures. This was not evidence that NMN relieves menopause symptoms or that all midlife women benefit. Yoshino and colleagues.
The participant description matters: postmenopause was a characteristic of the group, not the name of the outcome being improved. A metabolic measure cannot be substituted for fewer hot flashes, better sleep or a change in quality of life. Nor does this study establish prevention or treatment of diabetes.
Our NMN evidence overview introduces the broader science. Here, we focus on matching women's-health claims to the actual study question before buying.
Why the 2026 menopause study is not an NMN study
Check the ingredient name before transferring a headline to another supplement. The 2026 pilot used nicotinamide riboside plus pterostilbene, not NMN. It enrolled 40 women over 35, including 32 reporting menopause-transition symptoms. Some symptoms improved compared with baseline after seven days, but the study was open-label and lacked a placebo comparison. The company Elysium Health funded it, and several authors disclosed company employment. Holmes and colleagues: methods and disclosures.
That design provides a reason for further testing, not a way to separate supplement effects from expectations or symptoms changing over time. It also cannot identify which ingredient in the combination contributed to a change. These limitations do not erase the observations; they limit what a shopper can conclude.
Match the claim to the evidence
A shared connection to NAD+ does not make different interventions interchangeable. Use this original comparison to keep the question, product and outcome attached to each other.
| Claim you encounter | What to check | What would be an overreach? |
|---|---|---|
| “Studied in postmenopausal women” | Which health characteristics and measured outcomes? | Assuming the study treated menopause symptoms |
| “NAD+ supplement research” | NMN, NR, or a combination? What finished preparation? | Transferring results between ingredients or brands |
| “Participants felt better” | Compared with baseline only, or a blinded control? | Attributing every change to the supplement |
| “Well tolerated in a trial” | For how long, in whom, and with which exclusions? | Calling long-term use safe for everyone |
For the ingredient distinction itself, see our NMN and NR comparison. When reviewing a claim, open the paper rather than relying on an abbreviation in the headline.
Does broader NMN research settle the question?
Short-term tolerability is not proof of symptom relief or long-term safety. A July 2026 systematic review included 15 randomized trials of oral NMN or related preparations, with ten contributing safety data. Study durations ranged from 14 days to 24 weeks. It found no clear increase in adverse events, but broad metabolic benefits were not evident. The authors called for larger, longer studies. Yang and colleagues, systematic review.
That review does not supply a menopause-treatment recommendation. It also cannot establish that a retail product delivers the same findings. Research regimens are not personal serving instructions, and a blend may introduce ingredients that were never part of the study you read.
Turn your goal into a useful next step
Keep symptom care and supplement shopping as separate decisions. If hot flashes or night sweats are disrupting daily life, discuss evidence-based options with a qualified clinician. The Menopause Society's 2023 position statement did not recommend supplements or herbal remedies for vasomotor symptom treatment. That statement predates the 2026 pilot; it should not be presented as a direct assessment of that new paper. Professional guidance.
Before you buy, finish these sentences:
- “The specific outcome I want help with is …”
- “The evidence I found tested … in … and measured …”
- “The important difference from my situation is …”
- “The question I still need answered is …”
For example, if the goal is fewer hot flashes but the cited paper measured muscle insulin response, the outcome does not match. If the goal is general supplement consideration, review the complete label, your medicines and health history without treating the product as symptom therapy. Do not stop or replace prescribed care on the basis of a supplement headline.
If NMN Daily remains on your shortlist, use its current product information for that separate label review. Resolve unanswered questions before adding it to a routine.
The practical conclusion: choose evidence that matches the ingredient, person and outcome—not just a familiar life stage in the title. You do not need to turn an interesting early finding into a purchase promise.
Review NMN Daily on its own terms
Explore the current product details and complete formula as part of an informed supplement decision.
The cited studies did not test Yesnap NMN Daily. This article does not claim that it treats menopause symptoms, changes hormones or replaces medical care.
Frequently asked questions
Does a study in postmenopausal women prove a menopause benefit?
No. Read what was measured. A study's population and its outcome answer different questions; the 2021 NMN trial was a metabolic study.
Can I apply NR research to NMN?
Not directly. A result belongs to the tested ingredient or combination, population and protocol. A shared biological pathway does not clear that gap.
Do these studies show that NMN replaces hormone therapy?
No. They do not establish that comparison. Decisions about symptom treatment belong in an individualized conversation with a qualified clinician.
Should I copy the amount used in a trial?
No. Trial regimens are part of defined research protocols, not personal instructions for a different retail formula.
Written by Yesnap. Updated September 29, 2026. Educational information; not a treatment or dosing recommendation.
Sources and evidence limits
- Yoshino et al., 2021 — randomized controlled NMN trial; small, selected population and metabolic outcomes.
- Holmes et al., 2026 — seven-day NR combination pilot; open-label, no placebo, commercially funded. Not NMN evidence.
- Yang et al., 2026 — systematic review of short-term NMN/related trials; does not establish long-term or menopause-specific effects.
- The Menopause Society, 2023 position statement — evidence-based vasomotor symptom guidance, published before the 2026 pilot.
All sources accessed September 29, 2026. No study figure or participant image is reproduced.